BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, Vellone M, Giuliante F, Nuzzo G, Barone C. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15:933-939. [PMID: 15151951 DOI: 10.1093/annonc/mdh217] [Cited by in Crossref: 231] [Cited by in F6Publishing: 188] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Garufi C, Ettorre GM, Vanni B, Torsello A, Terzoli E. Neoadjuvant chemotherapy for metastatic colon cancer: too much caution and still too much to be assessed. J Clin Oncol. 2006;24:2217-2218; author reply 2218-2219. [PMID: 16682743 DOI: 10.1200/JCO.2006.05.6358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
2 Lenz H. First-line combination treatment of colorectal cancer with hepatic metastases: Choosing a targeted agent. Cancer Treatment Reviews 2008;34:S3-7. [DOI: 10.1016/s0305-7372(08)70002-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
3 Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, Fuchs C, Ramanathan RK, Williamson SK, Morton RF. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005;16:425-429. [PMID: 15677624 DOI: 10.1093/annonc/mdi092] [Cited by in Crossref: 117] [Cited by in F6Publishing: 93] [Article Influence: 6.9] [Reference Citation Analysis]
4 Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability. Ann Surg Oncol. 2007;14:3301-3309. [PMID: 17891443 DOI: 10.1245/s10434-007-9549-7] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
5 Kuvshinoff B, Fong Y. Surgical therapy of liver metastases. Semin Oncol 2007;34:177-85. [PMID: 17560979 DOI: 10.1053/j.seminoncol.2007.03.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
6 Qiu M, Hu J, Yang D, Cosgrove DP, Xu R. Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget. 2015;6:38658-38666. [PMID: 26484417 DOI: 10.18632/oncotarget.6130] [Cited by in Crossref: 108] [Cited by in F6Publishing: 108] [Article Influence: 18.0] [Reference Citation Analysis]
7 Thomay AA, Charpentier KP. Optimizing resection for "responding" hepatic metastases after neoadjuvant chemotherapy. J Surg Oncol 2010;102:1002-8. [PMID: 20734423 DOI: 10.1002/jso.21694] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Oussoultzoglou E, Bachellier P, Rosso E, Scurtu R, Lucescu I, Greget M, Jaeck D. Right portal vein embolization before right hepatectomy for unilobar colorectal liver metastases reduces the intrahepatic recurrence rate. Ann Surg 2006;244:71-9. [PMID: 16794391 DOI: 10.1097/01.sla.0000217609.26178.35] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
9 Zdenkowski N, Chen S, van der Westhuizen A, Ackland S. Curative strategies for liver metastases from colorectal cancer: a review. Oncologist. 2012;17:201-211. [PMID: 22234631 DOI: 10.1634/theoncologist.2011-0300] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
10 Benoist S, Nordlinger B. Neoadjuvant treatment before resection of liver metastases. Eur J Surg Oncol 2007;33 Suppl 2:S35-41. [PMID: 17981428 DOI: 10.1016/j.ejso.2007.09.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
11 Masi G, Vasile E, Loupakis F, Bursi S, Ricci S, Petrini I, Fontana A, Allegrini G, Falcone A. Triplet Combination of Fluoropyrimidines, Oxaliplatin, and Irinotecan in the First-Line Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer 2008;7:7-14. [DOI: 10.3816/ccc.2008.n.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Buie WD, Attard JA. Follow-up recommendations for colon cancer. Clin Colon Rectal Surg 2005;18:232-43. [PMID: 20011306 DOI: 10.1055/s-2005-916284] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
13 Hubert C, Fervaille C, Sempoux C, Horsmans Y, Humblet Y, Machiels J, Zech F, Ceratti A, Gigot J. Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases. Surgery 2010;147:185-94. [DOI: 10.1016/j.surg.2009.01.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
14 Popescu I, Alexandrescu ST. Surgical options for initially unresectable colorectal liver metastases. HPB Surg 2012;2012:454026. [PMID: 23082042 DOI: 10.1155/2012/454026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
15 Bolhuis K, Kos M, van Oijen MGH, Swijnenburg RJ, Punt CJA. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review. Eur J Cancer 2020;141:225-38. [PMID: 33189037 DOI: 10.1016/j.ejca.2020.09.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
16 Sperti E, Faggiuolo R, Gerbino A, Magnino A, Muratore A, Ortega C, Ferraris R, Leone F, Capussotti L, Aglietta M. Outcome of Metastatic Colorectal Cancer: Analysis of a Consecutive Series of 229 Patients. The Impact of a Multidisciplinary Approach. Diseases of the Colon & Rectum 2006;49:1596-601. [DOI: 10.1007/s10350-006-0662-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
17 Sturesson C, Nilsson J, Eriksson S, Spelt L, Andersson R. Limiting factors for liver regeneration after a major hepatic resection for colorectal cancer metastases. HPB (Oxford). 2013;15:646-652. [PMID: 23458360 DOI: 10.1111/hpb.12040] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
18 Townsend AR, Chong LC, Karapetis C, Price TJ. Selective internal radiation therapy for liver metastases from colorectal cancer. Cancer Treat Rev 2016;50:148-54. [PMID: 27690234 DOI: 10.1016/j.ctrv.2016.09.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
19 Symonds LK, Cohen SA. Use of perioperative chemotherapy in colorectal cancer metastatic to the liver. Gastroenterol Rep (Oxf) 2019;7:301-11. [PMID: 31687149 DOI: 10.1093/gastro/goz035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
20 Dawood S, Sirohi B, Shrikhande SV, Toh HC, Eng C. Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer: A Large Population Based Study. Indian J Surg Oncol 2015;6:198-206. [PMID: 27217664 DOI: 10.1007/s13193-015-0419-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
21 Power DG, Lichtman SM. Chemotherapy for the Elderly Patient With Colorectal Cancer. The Cancer Journal 2010;16:241-52. [DOI: 10.1097/ppo.0b013e3181e07690] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
22 Nordlinger B, Vauthey JN, Poston G, Benoist S, Rougier P, Van Cutsem E. The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. Clin Colorectal Cancer. 2010;9:212-218. [PMID: 20920992 DOI: 10.3816/ccc.2010.n.031] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
23 Gonzalez RJ, Barnett CC Jr. A technique for safely teaching major hepatectomy to surgical residents. Am J Surg 2008;195:521-5. [PMID: 18304505 DOI: 10.1016/j.amjsurg.2007.02.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
24 Price TJ, Tebbutt NC, Karapetis CS, Segelov E, Pavlakis N, Cunningham D, Sobrero AF, Haller DG, Shapiro JD. Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clinical Colorectal Cancer 2010;9:8-14. [DOI: 10.3816/ccc.2010.n.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
25 de Haas RJ, Wicherts DA, Flores E, Ducreux M, Lévi F, Paule B, Azoulay D, Castaing D, Lemoine A, Adam R. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol 2010;17:1010-23. [PMID: 20052553 DOI: 10.1245/s10434-009-0887-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
26 Garcea G, Ong SL, Maddern GJ. Inoperable colorectal liver metastases: a declining entity? Eur J Cancer. 2008;44:2555-2572. [PMID: 18755585 DOI: 10.1016/j.ejca.2008.07.028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
27 Piltch A, Zhang F, Hayashi J. Culture and characterization of thymic epithelium from autoimmune NZB and NZB/W mice. Cell Immunol 1990;131:325-37. [PMID: 2242501 DOI: 10.1016/0008-8749(90)90258-s] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 0.7] [Reference Citation Analysis]
28 Leichman L. Neoadjuvant chemotherapy for disseminated colorectal cancer: changing the paradigm. J Clin Oncol 2006;24:3817-8. [PMID: 16921031 DOI: 10.1200/JCO.2006.07.2546] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
29 Tanaka K, Takakura H, Takeda K, Matsuo K, Nagano Y, Endo I. Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg. 2009;250:935-942. [PMID: 19953712 DOI: 10.1097/sla.0b013e3181b0c6e4] [Cited by in Crossref: 69] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
30 Costi R, Leonardi F, Zanoni D, Violi V, Roncoroni L. Palliative care and end-stage colorectal cancer management: The surgeon meets the oncologist. World J Gastroenterol 2014; 20(24): 7602-7621 [PMID: 24976699 DOI: 10.3748/wjg.v20.i24.7602] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
31 Kemeny N. The management of resectable and unresectable liver metastases from colorectal cancer. Curr Opin Oncol. 2010;22:364-373. [PMID: 20520544 DOI: 10.1097/cco.0b013e32833a6c8a] [Cited by in Crossref: 57] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
32 Figueras J, Torras J, Valls C, Llado L, Ramos E, Marti-Ragué J, Serrano T, Fabregat J. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum. 2007;50:478-488. [PMID: 17279302 DOI: 10.1007/s10350-006-0817-6] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 4.9] [Reference Citation Analysis]
33 Niu R, Yan TD, Zhu JC, Black D, Chu F, Morris DL. Recurrence and Survival Outcomes after Hepatic Resection with or without Cryotherapy for Liver Metastases from Colorectal Carcinoma. Ann Surg Oncol 2007;14:2078-87. [DOI: 10.1245/s10434-007-9400-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
34 Rossi L, Zullo A, Zoratto F, Papa A, Strudel M, Colonna M, Tomao S. Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases. Oncol Rev 2012;6:e6. [PMID: 25992208 DOI: 10.4081/oncol.2012.e6] [Reference Citation Analysis]
35 Mohammad WM, Martel G, Mimeault R, Fairfull-Smith RJ, Auer RC, Balaa FK. Evaluating agreement regarding the resectability of colorectal liver metastases: a national case-based survey of hepatic surgeons. HPB (Oxford). 2012;14:291-297. [PMID: 22487066 DOI: 10.1111/j.1477-2574.2012.00440.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
36 Leite D, Kater FR. Conversion treatment of hepatic metastases of colon adenocarcinoma by bevacizumab and FOLFOX. Anticancer Drugs 2011;22 Suppl 2:S1-7. [PMID: 21768791 DOI: 10.1097/01.cad.0000398726.60837.27] [Reference Citation Analysis]
37 Bathe OF, Ernst S, Sutherland FR, Dixon E, Butts C, Bigam D, Holland D, Porter GA, Koppel J, Dowden S. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer. 2009;9:156. [PMID: 19457245 DOI: 10.1186/1471-2407-9-156] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
38 Di Benedetto F, Berretta M, D'Amico G, Montalti R, De Ruvo N, Cautero N, Guerrini GP, Ballarin R, Spaggiari M, Tarantino G, Di Sandro S, Pecchi A, Luppi G, Gerunda GE. Liver resection for colorectal metastases in older adults: A paired matched analysis. J Am Geriatr Soc. 2011;59:2282-2290. [PMID: 22188075 DOI: 10.1111/j.1532-5415.2011.03734.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
39 Hasselgren K, Malagò M, Vyas S, Campos RR, Brusadin R, Linecker M, Petrowsky H, Clavien PA, Machado MA, Hernandez-Alejandro R, Wanis K, Valter L, Sandström P, Björnsson B. Neoadjuvant chemotherapy does not affect future liver remnant growth and outcomes of associating liver partition and portal vein ligation for staged hepatectomy. Surgery 2017;161:1255-65. [PMID: 28081953 DOI: 10.1016/j.surg.2016.11.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
40 Folprecht G. Neoadjuvant chemotherapy for non-/resectable metastases. European Journal of Cancer 2011;47:S52-60. [DOI: 10.1016/s0959-8049(11)70147-2] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
41 Okines A, Cunningham D. Current perspective: Bevacizumab in colorectal cancer – A time for reappraisal? European Journal of Cancer 2009;45:2452-61. [DOI: 10.1016/j.ejca.2009.06.028] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
42 Moehler M, Teufel A, Galle PR. New Chemotherapeutic Strategies in Colorectal Cancer. In: Büchler MW, Weitz J, Ulrich B, Heald RJ, editors. Rectal Cancer Treatment. Berlin/Heidelberg: Springer-Verlag; 2005. pp. 250-9. [DOI: 10.1007/3-540-27449-9_28] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
43 Sotelo Lezama MJ, Sastre Valera J, Díaz-Rubio García E. Impact of cetuximab in current treatment of metastatic colorectal cancer. Expert Opin Biol Ther 2014;14:387-99. [PMID: 24479733 DOI: 10.1517/14712598.2014.883376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 Saif MW. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. World J Gastroenterol 2009; 15(31): 3855-3864 [PMID: 19701965 DOI: 10.3748/wjg.15.3855] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
45 Poston GJ. Staging of advanced colorectal cancer. Surg Oncol Clin N Am 2008;17:503-17, viii. [PMID: 18486880 DOI: 10.1016/j.soc.2008.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
46 Kuehrer I. Multimodal treatment of metastatic colorectal cancer. Acta Chir Iugosl 2006;53:51-5. [PMID: 17139885 DOI: 10.2298/aci0602051k] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
47 Zaniboni A, Torri V, Tinazzi A, Codignola C, Faggiuolo R, Sperti E. Neoadjuvant Oxaliplatin-based Chemotherapy for Liver Metastases from Colorectal Cancer. An Italian Survey. Tumori 2005;91:383-7. [DOI: 10.1177/030089160509100501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
48 Okuno M, Hatano E, Nishino H, Seo S, Taura K, Uemoto S. Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases?: A systematic review. Eur J Surg Oncol 2017;43:1003-12. [PMID: 27624917 DOI: 10.1016/j.ejso.2016.08.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
49 Ismaili N. Treatment of colorectal liver metastases. World J Surg Oncol. 2011;9:154. [PMID: 22115124 DOI: 10.1186/1477-7819-9-154] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
50 Yan TD, Sim J, Black D, Niu R, Morris DL. Systematic review on safety and efficacy of repeat hepatectomy for recurrent liver metastases from colorectal carcinoma. Ann Surg Oncol. 2007;14:2069-2077. [PMID: 17440785 DOI: 10.1245/s10434-007-9388-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
51 Hubbard JM, Alberts SR. Treatment of liver-limited metastatic colorectal cancer. Cancer J 2010;16:235-40. [PMID: 20526102 DOI: 10.1097/PPO.0b013e3181e075e9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, Pessi MA, Prochilo T, Quadri A, Gatta G, de Braud F, Wils J. Colon cancer. Critical Reviews in Oncology/Hematology 2010;74:106-33. [DOI: 10.1016/j.critrevonc.2010.01.010] [Cited by in Crossref: 117] [Cited by in F6Publishing: 115] [Article Influence: 9.8] [Reference Citation Analysis]
53 De Stefano A, Carlomagno C. Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(29): 9732-9743 [PMID: 25110411 DOI: 10.3748/wjg.v20.i29.9732] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
54 Connor AA, Burkes R, Gallinger S. Strategies in the Multidisciplinary Management of Synchronous Colorectal Cancer and Resectable Liver Metastases. Curr Colorectal Cancer Rep 2014;10:227-38. [DOI: 10.1007/s11888-014-0222-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Ishibashi K, Ishida H, Ohsawa T, Okada N, Kumamoto K, Haga N. Impact of hepatic lymph node metastasis on survival of patients with synchronous resectable or unresectable liver metastases of colorectal cancer. Tech Coloproctol 2013;17:51-7. [PMID: 22936589 DOI: 10.1007/s10151-012-0881-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
56 Wicherts D, de Haas R, Adam R. Bringing unresectable liver disease to resection with curative intent. European Journal of Surgical Oncology (EJSO) 2007;33:S42-51. [DOI: 10.1016/j.ejso.2007.09.017] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 3.1] [Reference Citation Analysis]
57 Andreou A, Aloia TA, Brouquet A, Dickson PV, Zimmitti G, Maru DM, Kopetz S, Loyer EM, Curley SA, Abdalla EK, Vauthey JN. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 2013;257:1079-88. [PMID: 23426338 DOI: 10.1097/SLA.0b013e318283a4d1] [Cited by in Crossref: 125] [Cited by in F6Publishing: 56] [Article Influence: 13.9] [Reference Citation Analysis]
58 Coimbra FJ, Ribeiro HS, Marques MC, Herman P, Chojniak R, Kalil AN, Wiermann EG, Cavallero SR, Coelho FF, Fernandes PH, Silvestrini AA, Almeida MF, de Araújo AL, Pitombo M, Teixeira HM, Waechter FL, Ferreira FG, Diniz AL, D'Ippolito G, D'Ippolito G, Begnami MD, Prolla G, Balzan SM, de Oliveira TB, Szultan LA, Lendoire J, Torres OJ. FIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATION. Arq Bras Cir Dig 2015;28:222-30. [PMID: 26734788 DOI: 10.1590/S0102-6720201500040002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
59 Alberts SR, Wagman LD. Chemotherapy for colorectal cancer liver metastases. Oncologist. 2008;13:1063-1073. [PMID: 18838438 DOI: 10.1634/theoncologist.2008-0142] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
60 Leonard GD, Brenner B, Kemeny NE. Neoadjuvant Chemotherapy Before Liver Resection for Patients With Unresectable Liver Metastases From Colorectal Carcinoma. JCO 2005;23:2038-48. [DOI: 10.1200/jco.2005.00.349] [Cited by in Crossref: 224] [Cited by in F6Publishing: 84] [Article Influence: 13.2] [Reference Citation Analysis]
61 Shimada H, Tanaka K, Endou I, Ichikawa Y. Treatment for colorectal liver metastases: a review. Langenbecks Arch Surg. 2009;394:973-983. [PMID: 19582473 DOI: 10.1007/s00423-009-0530-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
62 Sobrero A, De Cian F, Andretta V, Pessino A. Objectives of chemotherapy for unresectable liver metastases: Best response or resection? European Journal of Cancer Supplements 2007;5:317-21. [DOI: 10.1016/s1359-6349(07)70059-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
63 de Liguori Carino N, O’Reilly DA, Dajani K, Ghaneh P, Poston GJ, Wu AV. Perioperative use of the LiMON method of indocyanine green elimination measurement for the prediction and early detection of post-hepatectomy liver failure. Eur J Surg Oncol. 2009;35:957-962. [PMID: 19250796 DOI: 10.1016/j.ejso.2009.02.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
64 Poston G, Adam R, Vauthey JN. Downstaging or downsizing: time for a new staging system in advanced colorectal cancer? J Clin Oncol 2006;24:2702-6. [PMID: 16782909 DOI: 10.1200/JCO.2006.05.8404] [Cited by in Crossref: 31] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
65 Barugel ME, Vargas C, Krygier Waltier G. Metastatic colorectal cancer: recent advances in its clinical management. Expert Review of Anticancer Therapy 2014;9:1829-47. [DOI: 10.1586/era.09.143] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
66 Mandalà M, Mosconi S, Quadri A, Milesi L, Labianca R. Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer. Expert Rev Anticancer Ther. 2007;7:887-897. [PMID: 17555399 DOI: 10.1586/14737140.7.6.887] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
67 Pessaux P, Chenard MP, Bachellier P, Jaeck D. Consequences of chemotherapy on resection of colorectal liver metastases. J Visc Surg. 2010;147:e193-e201. [PMID: 20655821 DOI: 10.1016/j.jviscsurg.2010.06.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
68 Sharma S, Camci C, Jabbour N. Management of hepatic metastasis from colorectal cancers: an update. J Hepatobiliary Pancreat Surg 2008;15:570-80. [PMID: 18987925 DOI: 10.1007/s00534-008-1350-x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 3.9] [Reference Citation Analysis]
69 Saab R, Furman WL. Epidemiology and management options for colorectal cancer in children. Paediatr Drugs 2008;10:177-92. [PMID: 18454570 DOI: 10.2165/00148581-200810030-00006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
70 Nuzzo G, Giuliante F, Ardito F, Vellone M, Pozzo C, Cassano A, Giovannini I, Barone C. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg. 2007;11:318-324. [PMID: 17458605 DOI: 10.1007/s11605-006-0070-2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
71 Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamata H, Koisumi J. Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer. Surg Today 2013;43:1088-94. [PMID: 23143145 DOI: 10.1007/s00595-012-0416-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
72 Giakoustidis A, Neofytou K, Khan A, Mudan S. Addition of bevacizumab to preoperative chemotherapy for colorectal liver metastases does not increase perioperative morbidity and mortality. Hepat Oncol 2014;1:363-75. [PMID: 30190972 DOI: 10.2217/hep.14.17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Mcloughlin JM, Jensen EH, Malafa M. Resection of Colorectal Liver Metastases: Current Perspectives. Cancer Control 2017;13:32-41. [DOI: 10.1177/107327480601300105] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 11.2] [Reference Citation Analysis]
74 Petrelli NJ, Abbruzzese J, Mansfield P, Minsky B. Hepatic Resection: The Last Surgical Frontier for Colorectal Cancer. JCO 2005;23:4475-7. [DOI: 10.1200/jco.2005.05.025] [Cited by in Crossref: 140] [Cited by in F6Publishing: 10] [Article Influence: 8.2] [Reference Citation Analysis]
75 Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38-47. [PMID: 19942479 DOI: 10.1016/s1470-2045(09)70330-4] [Cited by in Crossref: 653] [Cited by in F6Publishing: 253] [Article Influence: 50.2] [Reference Citation Analysis]
76 Chong G, Cunningham D. Improving long-term outcomes for patients with liver metastases from colorectal cancer. J Clin Oncol. 2005;23:9063-9066. [PMID: 16301589 DOI: 10.1200/jco.2005.04.4669] [Cited by in Crossref: 37] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
77 O'reilly D, Chaudhari M, Ballal M, Ghaneh P, Wu A, Poston G. The Oncosurge strategy for the management of colorectal liver metastases – An external validation study. European Journal of Surgical Oncology (EJSO) 2008;34:538-40. [DOI: 10.1016/j.ejso.2007.04.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
78 Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1271-1280. [PMID: 16955381 DOI: 10.1245/s10434-006-9045-5] [Cited by in Crossref: 354] [Cited by in F6Publishing: 294] [Article Influence: 22.1] [Reference Citation Analysis]
79 Rossi L, Vakiarou F, Zoratto F, Bianchi L, Papa A, Basso E, Verrico M, Lo Russo G, Evangelista S, Rinaldi G, Perrone-Congedi F, Spinelli GP, Stati V, Caruso D, Prete A, Tomao S. Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). Cancer Manag Res. 2013;5:377-385. [PMID: 24399885 DOI: 10.2147/cmar.s47986] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
80 Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006;93:872-878. [PMID: 16671066 DOI: 10.1002/bjs.5346] [Cited by in Crossref: 204] [Cited by in F6Publishing: 169] [Article Influence: 12.8] [Reference Citation Analysis]
81 Juez I, Rubio C, Figueras J. Multidisciplinary approach of colorectal liver metastases. Clin Transl Oncol. 2011;13:721-727. [PMID: 21975333 DOI: 10.1007/s12094-011-0722-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
82 Zhao R, Zhu J, Ji X, Cai J, Wan F, Li Q, Zhong B, Tucker S, Wang D. A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer. Jpn J Clin Oncol 2010;40:10-6. [PMID: 19773270 DOI: 10.1093/jjco/hyp114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
83 Lubezky N, Winograd E, Papoulas M, Lahat G, Shacham-Shmueli E, Geva R, Nakache R, Klausner J, Ben-Haim M. Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases. J Gastrointest Surg. 2013;17:527-532. [PMID: 23299220 DOI: 10.1007/s11605-012-2108-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
84 Nasti G, Ottaiano A, Berretta M, Delrio P, Izzo F, Cassata A, Romano C, Facchini G, Scala D, Mastro A, Romano G, Perri F, Iaffaioli RV. Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. Cancer Chemother Pharmacol 2010;66:209-18. [DOI: 10.1007/s00280-010-1297-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
85 Nesbitt C, Glendinning RJ, Byrne C, Poston GJ. Factors that influence treatment strategies in advanced colorectal cancer. Eur J Surg Oncol 2007;33 Suppl 2:S88-94. [PMID: 18023553 DOI: 10.1016/j.ejso.2007.09.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
86 Power DG, Kemeny NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol. 2010;28:2300-2309. [PMID: 20368552 DOI: 10.1200/jco.2009.26.9340] [Cited by in Crossref: 53] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
87 Shen W, Wang CY, Wang XH, Fu ZX. Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res 2009;28:81. [PMID: 19527508 DOI: 10.1186/1756-9966-28-81] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
88 Kim KY, Kim NK, Cha IH, Ahn JB, Choi JS, Choi GH, Lim JS, Lee KY, Baik SH, Min BS, Hur H, Roh JK, Shin SJ. Novel methods for clinical risk stratification in patients with colorectal liver metastases. Cancer Res Treat 2015;47:242-50. [PMID: 25483744 DOI: 10.4143/crt.2014.066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
89 Spelt L, Hermansson L, Tingstedt B, Andersson R. Influence of preoperative chemotherapy on the intraoperative and postoperative course of liver resection for colorectal cancer metastases. World J Surg. 2012;36:157-163. [PMID: 22086255 DOI: 10.1007/s00268-011-1342-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
90 Wu B, Yang JK, Zhu YJ. Conversion therapy for colorectal cancer patients with potentially resectable liver metastases. Shijie Huaren Xiaohua Zazhi 2014; 22(4): 533-540 [DOI: 10.11569/wcjd.v22.i4.533] [Reference Citation Analysis]
91 Uetake H, Tanaka S, Ishikawa T, Sugihara K, Arii S. Fate of metastatic foci after chemotherapy and usefulness of contrast-enhanced intraoperative ultrasonography to detect minute hepatic lesions. J Hepatobiliary Pancreat Sci 2012;19:509-14. [PMID: 22539087 DOI: 10.1007/s00534-012-0510-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
92 Lee KH, Kim HO, Yoo CH, Son BH, Park YL, Cho YK, Kim H, Han WK. Comparison of radiofrequency ablation and resection for hepatic metastasis from colorectal cancer. Korean J Gastroenterol. 2012;59:218-223. [PMID: 22460570 DOI: 10.4166/kjg.2012.59.3.218] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
93 Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009;101:1033-8. [PMID: 19789532 DOI: 10.1038/sj.bjc.6605259] [Cited by in Crossref: 128] [Cited by in F6Publishing: 106] [Article Influence: 9.8] [Reference Citation Analysis]
94 Rouyer M, Smith D, Laurent C, Becouarn Y, Guimbaud R, Michel P, Tubiana-mathieu N, Balestra A, Jové J, Robinson P, Noize P, Moore N, Ravaud A, Fourrier-réglat A; on behalf of the ETNA study group. Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort. Targ Oncol 2016;11:83-92. [DOI: 10.1007/s11523-015-0377-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Marcolino Assis-júnior E, Melo AT, Pereira VBM, Wong DVT, Sousa NRP, Oliveira CMG, Malveira LRC, Moreira LS, Souza MHLP, Almeida PRC, Lima-júnior RCP. Dual effect of silymarin on experimental non-alcoholic steatohepatitis induced by irinotecan. Toxicology and Applied Pharmacology 2017;327:71-9. [DOI: 10.1016/j.taap.2017.04.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
96 Gomez D, De Rosa A, Addison A, Brooks A, Malik HZ, Cameron IC. Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier? Int J Surg. 2013;11:507-513. [PMID: 23660586 DOI: 10.1016/j.ijsu.2013.04.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
97 Martin J, Petrillo A, Smyth EC, Shaida N, Khwaja S, Cheow H, Duckworth A, Heister P, Praseedom R, Jah A, Balakrishnan A, Harper S, Liau S, Kosmoliaptsis V, Huguet E. Colorectal liver metastases: Current management and future perspectives. World J Clin Oncol 2020; 11(10): 761-808 [PMID: 33200074 DOI: 10.5306/wjco.v11.i10.761] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
98 Leichman L. The Role of Chemotherapy in the Curative Treatment of Patients with Liver Metastases from Colorectal Cancer. Surgical Oncology Clinics of North America 2007;16:537-56. [DOI: 10.1016/j.soc.2007.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
99 Pavel MC, Casanova R, Estalella L, Memba R, Llàcer-Millán E, Achalandabaso M, Julià E, Geoghegan J, Jorba R. The effect of preoperative chemotherapy on liver regeneration after portal vein embolization/ligation or liver resection in patients with colorectal liver metastasis: a systematic review protocol. Syst Rev 2020;9:279. [PMID: 33276812 DOI: 10.1186/s13643-020-01545-w] [Reference Citation Analysis]
100 Verghese M, Pathak S, Poston GJ. Increasing long-term survival in advanced colorectal cancer. Eur J Surg Oncol 2007;33 Suppl 2:S1-4. [PMID: 18036766 DOI: 10.1016/j.ejso.2007.09.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
101 Wagman LD. Importance of Response to Neoadjuvant Therapy in Patients With Liver-Limited mCRC When the Intent Is Resection and/or Ablation. Clinical Colorectal Cancer 2013;12:223-32. [DOI: 10.1016/j.clcc.2013.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
102 Katz M, Vauthey JN. Potentially curable metastatic colorectal cancer. Curr Oncol Rep 2008;10:225-31. [PMID: 18765153 DOI: 10.1007/s11912-008-0035-6] [Reference Citation Analysis]
103 Welsh FK, Tilney HS, Tekkis PP, John TG, Rees M. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer. 2007;96:1037-1042. [PMID: 17353923 DOI: 10.1038/sj.bjc.6603670] [Cited by in Crossref: 143] [Cited by in F6Publishing: 118] [Article Influence: 9.5] [Reference Citation Analysis]
104 Ji JH, Park SH, Lee J, Kim TW, Hong YS, Kim K, Kim SY, Baek JY, Kang HJ, Shin SJ, Shim BY, Park YS. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. Cancer Chemother Pharmacol 2013;72:223-30. [DOI: 10.1007/s00280-013-2190-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
105 Cauchy F, Aussilhou B, Dokmak S, Fuks D, Gaujoux S, Farges O, Faivre S, Lepillé D, Belghiti J. Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Ann Surg 2012;256:746-52; discussion 752-4. [PMID: 23095618 DOI: 10.1097/SLA.0b013e3182738204] [Cited by in Crossref: 52] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
106 Ng JK, Urbanski SJ, Mangat N, McKay A, Sutherland FR, Dixon E, Dowden S, Ernst S, Bathe OF. Colorectal liver metastases contract centripetally with a response to chemotherapy: a histomorphologic study. Cancer. 2008;112:362-371. [PMID: 18041069 DOI: 10.1002/cncr.23184] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
107 Biasco G, Derenzini E, Grazi G, Ercolani G, Ravaioli M, Pantaleo M, Brandi G. Treatment of hepatic metastases from colorectal cancer: Many doubts, some certainties. Cancer Treatment Reviews 2006;32:214-28. [DOI: 10.1016/j.ctrv.2005.12.011] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 4.4] [Reference Citation Analysis]
108 Chan G, Chee CE. Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer. Cancers (Basel) 2020;12:E3535. [PMID: 33256170 DOI: 10.3390/cancers12123535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
109 Bruera G, Cannita K, Giuliante F, Baldi PL, Vicentini R, Marchetti P, Nuzzo G, Antonucci A, Ficorella C, Ricevuto E. Effectiveness of Liver Metastasectomies in Patients With Metastatic Colorectal Cancer Treated With FIr-B/FOx Triplet Chemotherapy Plus Bevacizumab. Clinical Colorectal Cancer 2012;11:119-26. [DOI: 10.1016/j.clcc.2011.11.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
110 Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M; European Colorectal Metastases Treatment Group; Sixth International Colorectal Liver Metastases Workshop. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20:985-992. [PMID: 19153115 DOI: 10.1093/annonc/mdn735] [Cited by in Crossref: 243] [Cited by in F6Publishing: 209] [Article Influence: 18.7] [Reference Citation Analysis]
111 Abad A, Figueras J, Valls C, Carrato A, Pardo F, Díaz-Rubio E, Aranda E. Guidelines for the detection and treatment of liver metastases of colorectal cancer. Clin Transl Oncol 2007;9:723-30. [PMID: 18055327 DOI: 10.1007/s12094-007-0129-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
112 Reddy SK, Barbas AS, Clary BM. Synchronous colorectal liver metastases: is it time to reconsider traditional paradigms of management? Ann Surg Oncol. 2009;16:2395-2410. [PMID: 19506963 DOI: 10.1245/s10434-009-0372-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
113 Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005;23:7125-7134. [PMID: 16192596 DOI: 10.1200/jco.2005.08.722] [Cited by in Crossref: 183] [Cited by in F6Publishing: 62] [Article Influence: 10.8] [Reference Citation Analysis]
114 Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42:2212-2221. [PMID: 16904315 DOI: 10.1016/j.ejca.2006.04.012] [Cited by in Crossref: 326] [Cited by in F6Publishing: 318] [Article Influence: 20.4] [Reference Citation Analysis]
115 Shin SJ, Ahn JB, Choi JS, Choi GH, Lee KY, Baik SH, Min BS, Hur H, Roh JK, Kim NK. Implications of clinical risk score to predict outcomes of liver-confined metastasis of colorectal cancer. Surg Oncol 2012;21:e125-30. [PMID: 22560405 DOI: 10.1016/j.suronc.2012.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
116 Barone C, Nuzzo G, Cassano A, Basso M, Schinzari G, Giuliante F, D’Argento E, Trigila N, Astone A, Pozzo C. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97:1035-1039. [PMID: 17895897 DOI: 10.1038/sj.bjc.6603988] [Cited by in Crossref: 95] [Cited by in F6Publishing: 69] [Article Influence: 6.3] [Reference Citation Analysis]
117 Poston G, Adam R, Xu J, Byrne B, Esser R, Malik H, Wasan H, Xu J. The role of cetuximab in converting initially unresectable colorectal cancer liver metastases for resection. European Journal of Surgical Oncology 2017;43:2001-11. [DOI: 10.1016/j.ejso.2017.07.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
118 Ychou M, Rivoire M, Thezenas S, Quenet F, Delpero JR, Rebischung C, Letoublon C, Guimbaud R, Francois E, Ducreux M, Desseigne F, Fabre JM, Assenat E. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol. 2013;20:4289-4297. [PMID: 23955585 DOI: 10.1245/s10434-013-3217-x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 6.2] [Reference Citation Analysis]
119 Chiappa A, Makuuchi M, Lygidakis NJ, Zbar AP, Chong G, Bertani E, Sitzler PJ, Biffi R, Pace U, Bianchi PP. The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy. Crit Rev Oncol Hematol. 2009;72:65-75. [PMID: 19147371 DOI: 10.1016/j.critrevonc.2008.11.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
120 Fernandez R, Pappas SG, Bentrem DJ. Clinical Features of Metastatic Hepatic Malignancies. Cancer Treat Res 2016;168:185-202. [PMID: 29206370 DOI: 10.1007/978-3-319-34244-3_9] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
121 Chua YJ, Cunningham D. Neoadjuvant treatment of unresectable liver metastases from colorectal cancer. Clin Colorectal Cancer 2006;5:405-12. [PMID: 16635279 DOI: 10.3816/CCC.2006.n.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
122 Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases? World J Gastrointest Oncol 2018; 10(8): 211-220 [PMID: 30147847 DOI: 10.4251/wjgo.v10.i8.211] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
123 Kelly CM, Kemeny NE. Liver-directed therapy in metastatic colorectal cancer. Expert Rev Anticancer Ther. 2017;17:745-758. [PMID: 28636427 DOI: 10.1080/14737140.2017.1345629] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
124 Coimbra FJF, Pires TC, Junior WLDC, Diniz AL, Ribeiro HSDC. Avanços no tratamento cirúrgico das metástases hepáticas colorretais. Revista da Associação Médica Brasileira 2011;57:220-7. [DOI: 10.1590/s0104-42302011000200022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
125 Morine Y, Shimada M, Utsunomiya T. Evaluation and management of hepatic injury induced by oxaliplatin-based chemotherapy in patients with hepatic resection for colorectal liver metastasis. Hepatol Res. 2014;44:59-69. [PMID: 23551330 DOI: 10.1111/hepr.12107] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
126 de Jong KP. Review article: Multimodality treatment of liver metastases increases suitability for surgical treatment. Aliment Pharmacol Ther. 2007;26 Suppl 2:161-169. [PMID: 18081659 DOI: 10.1111/j.1365-2036.2007.03484.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
127 Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: Metastases to a single organ. World J Gastroenterol 2015; 21(41): 11767-11776 [PMID: 26557001 DOI: 10.3748/wjg.v21.i41.11767] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 100] [Article Influence: 16.0] [Reference Citation Analysis]
128 Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E. Role of cetuximab in first-line treatment of metastatic colorectal cancer. World J Gastroenterol 2014; 20(15): 4208-4219 [PMID: 24764659 DOI: 10.3748/wjg.v20.i15.4208] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
129 Recondo GJ, Díaz-Cantón E, de la Vega M, Greco M, Recondo GS, Valsecchi ME. Advances and new perspectives in the treatment of metastatic colon cancer. World J Gastrointest Oncol 2014; 6(7): 211-224 [PMID: 25024813 DOI: 10.4251/wjgo.v6.i7.211] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
130 Comella P, Massidda B, Filippelli G, Natale D, Farris A, Buzzi F, Tafuto S, Maiorino L, Palmeri S, De Lucia L, Mancarella S, Leo S, Roselli M, Lorusso V, De Cataldis G. Safety and Efficacy of Irinotecan plus High-Dose Leucovorin and Intravenous Bolus 5-Fluorouracil for Metastatic Colorectal Cancer: Pooled Analysis of Two Consecutive Southern Italy Cooperative Oncology Group Trials. Clinical Colorectal Cancer 2005;5:203-10. [DOI: 10.3816/ccc.2005.n.032] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
131 Kemeny NE, Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH, Jarnagin WR, Patel D, D‘Angelica M. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27:3465-3471. [PMID: 19470932 DOI: 10.1200/jco.2008.20.1301] [Cited by in Crossref: 190] [Cited by in F6Publishing: 72] [Article Influence: 14.6] [Reference Citation Analysis]
132 Adam R, Aloia T, Lévi F, Wicherts DA, de Haas RJ, Paule B, Bralet MP, Bouchahda M, Machover D, Ducreux M. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007;25:4593-4602. [PMID: 17925554 DOI: 10.1200/jco.2007.10.8126] [Cited by in Crossref: 154] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
133 Beppu T, Sakamoto Y, Hasegawa K, Honda G, Tanaka K, Kotera Y, Nitta H, Yoshidome H, Hatano E, Ueno M. A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2012;19:72-84. [PMID: 22020927 DOI: 10.1007/s00534-011-0460-z] [Cited by in Crossref: 87] [Cited by in F6Publishing: 83] [Article Influence: 8.7] [Reference Citation Analysis]
134 Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, Delpero JR, Rivoire M, Quénet F, Portier G. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol. 2008;62:195-201. [PMID: 17901955 DOI: 10.1007/s00280-007-0588-3] [Cited by in Crossref: 114] [Cited by in F6Publishing: 85] [Article Influence: 7.6] [Reference Citation Analysis]
135 Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, Mitry E, Rougier P, Nordlinger B. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939-45. [PMID: 16921046 DOI: 10.1200/JCO.2006.05.8727] [Cited by in Crossref: 409] [Cited by in F6Publishing: 116] [Article Influence: 25.6] [Reference Citation Analysis]
136 Shiomi K, Naito M, Sato T, Nakamura T, Nakashima H, Naito M, Mikubo M, Matsui Y, Watanabe M, Satoh Y. Effect of adjuvant chemotherapy after pulmonary metastasectomy on the prognosis of colorectal cancer. Ann Med Surg (Lond) 2017;20:19-25. [PMID: 28702182 DOI: 10.1016/j.amsu.2017.06.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
137 Cardella J, Coburn NG, Gagliardi A, Maier BA, Greco E, Last L, Smith AJ, Law C, Wright F. Compliance, attitudes and barriers to post-operative colorectal cancer follow-up. J Eval Clin Pract 2008;14:407-15. [PMID: 18373578 DOI: 10.1111/j.1365-2753.2007.00880.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
138 Pozzo C, Barone C, Kemeny NE. Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Cancer Treatment Reviews 2008;34:293-301. [DOI: 10.1016/j.ctrv.2008.01.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
139 Pathak S, Poston GJ. Colorectal liver metastases; the current scenario. Indian J Surg Oncol 2010;1:350-5. [PMID: 22693391 DOI: 10.1007/s13193-011-0066-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
140 Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311-1319. [PMID: 15870084 DOI: 10.1093/annonc/mdi246] [Cited by in Crossref: 461] [Cited by in F6Publishing: 378] [Article Influence: 27.1] [Reference Citation Analysis]
141 Papamichail M, Pizanias M, Heaton ND, M P, M P, Nd H. Minimizing the risk of small-for-size syndrome after liver surgery. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00230-7. [PMID: 34961675 DOI: 10.1016/j.hbpd.2021.12.005] [Reference Citation Analysis]
142 Pini S, Pinto C, Angelelli B, Giampalma E, Blotta A, Di Fabio F, Santini D, Golfieri R, Martoni AA. Multimodal Sequential Approach in Colorectal Cancer Liver Metastases: Hepatic Resection after Yttrium-90 Selective Internal Radiation Therapy and Cetuximab Rescue Treatment. Tumori 2010;96:157-9. [DOI: 10.1177/030089161009600126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Maher B, Ryan E, Little M, Boardman P, Stedman B. The management of colorectal liver metastases. Clinical Radiology 2017;72:617-25. [DOI: 10.1016/j.crad.2017.05.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
144 Berri RN, Abdalla EK. Curable metastatic colorectal cancer: recommended paradigms. Curr Oncol Rep 2009;11:200-8. [PMID: 19336012 DOI: 10.1007/s11912-009-0029-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
145 Nordlinger B, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulias V. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer. 2007;43:2037-2045. [PMID: 17766104 DOI: 10.1016/j.ejca.2007.07.017] [Cited by in Crossref: 178] [Cited by in F6Publishing: 153] [Article Influence: 11.9] [Reference Citation Analysis]
146 Yamaguchi T, Matsumoto H, Yasutome M, Mori T, Takahashi K. Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. Cancer Chemother Pharmacol 2011;67:629-35. [DOI: 10.1007/s00280-010-1368-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
147 Kim JY, Kim JS, Baek MJ, Kim CN, Choi WJ, Park DK, Namgung H, Lee SC, Lee SJ. Prospective multicenter phase II clinical trial of FOLFIRI chemotherapy as a neoadjuvant treatment for colorectal cancer with multiple liver metastases. J Korean Surg Soc 2013;85:154-60. [PMID: 24106681 DOI: 10.4174/jkss.2013.85.4.154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
148 Neumann UP, Seehofer D, Neuhaus P. The surgical treatment of hepatic metastases in colorectal carcinoma. Dtsch Arztebl Int. 2010;107:335-342. [PMID: 20532128 DOI: 10.3238/arztebl.2010.0335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 0.2] [Reference Citation Analysis]
149 Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Tabernero J, Teh C, Van Cutsem E;  Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17:1225-1239. [PMID: 22962059 DOI: 10.1634/theoncologist.2012-0121] [Cited by in Crossref: 284] [Cited by in F6Publishing: 255] [Article Influence: 28.4] [Reference Citation Analysis]
150 Ducreux M, Boige V, Leboulleux S, Malka D, Kergoat P, Dromain C, Elias D, de Baere T, Sabourin J, Duvillard P, Lasser P, Schlumberger M, Baudin E. A Phase II Study of Irinotecan with 5-Fluorouracil and Leucovorin in Patients with Pretreated Gastroenteropancreatic Well-Differentiated Endocrine Carcinomas. Oncology 2006;70:134-40. [DOI: 10.1159/000093004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
151 Kim CG, Ahn JB, Jung M, Beom SH, Kim C, Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, Min BS, Kim H, Koom WS, Shin SJ. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer. 2016;115:25-33. [PMID: 27228287 DOI: 10.1038/bjc.2016.161] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 11.0] [Reference Citation Analysis]
152 Abdalla EK. Commentary: Radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg. 2009;197:737-739. [PMID: 18789420 DOI: 10.1016/j.amjsurg.2008.06.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
153 Eichler K, Dufas T, Hammerstingl R, Gruber-rouh T, Vogl T, Zangos S. Hepatic Arterial Infusion with Irinotecan in Patients with Liver Metastases of Colorectal Cancer: Results of an Extended Phase I Study. Chemotherapy 2013;59:66-73. [DOI: 10.1159/000348579] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
154 Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F, Allegrini G, Brunetti IM, Pfanner E, Viti M, Goletti O, Filipponi F, Falcone A. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol. 2006;13:58-65. [PMID: 16372158 DOI: 10.1245/aso.2006.03.094] [Cited by in Crossref: 126] [Cited by in F6Publishing: 39] [Article Influence: 7.9] [Reference Citation Analysis]
155 Voorthuizen TV, van Gulik TM, Punt CJ. Defining resectability of colorectal liver metastases: how and why? Colorectal Cancer 2013;2:61-72. [DOI: 10.2217/crc.12.79] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
156 Vibert E, Canedo L, Adam R. Strategies to treat primary unresectable colorectal liver metastases. Semin Oncol. 2005;32:33-39. [PMID: 16360011 DOI: 10.1053/j.seminoncol.2005.07.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
157 Hewes JC, Dighe S, Morris RW, Hutchins RR, Bhattacharya S, Davidson BR. Preoperative chemotherapy and the outcome of liver resection for colorectal metastases. World J Surg. 2007;31:353-64; discussion 365. [PMID: 17219289 DOI: 10.1007/s00268-006-0103-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
158 Andres A, Majno PE, Morel P, Rubbia-brandt L, Giostra E, Gervaz P, Terraz S, Allal AS, Roth AD, Mentha G. Improved Long-Term Outcome of Surgery for Advanced Colorectal Liver Metastases: Reasons and Implications for Management on the Basis of a Severity Score. Ann Surg Oncol 2008;15:134-43. [DOI: 10.1245/s10434-007-9607-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.0] [Reference Citation Analysis]
159 Alberts SR, Poston GJ. Treatment advances in liver-limited metastatic colorectal cancer. Clin Colorectal Cancer. 2011;10:258-265. [PMID: 21820974 DOI: 10.1016/j.clcc.2011.06.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
160 Clark ME, Smith RR. Liver-directed therapies in metastatic colorectal cancer. J Gastrointest Oncol. 2014;5:374-387. [PMID: 25276410 DOI: 10.3978/j.issn.2078-6891.2014.064] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
161 Vitiello F, Ricci V, Martinelli E, Orditura M, Devita F, Galizia G, Ciardiello F. Complete pathological response of colorectal liver metastases after chemotherapy and bevacizumab treatment: a case report. Targ Oncol 2008;3:253-8. [DOI: 10.1007/s11523-008-0094-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
162 Min BS, Kim NK, Ahn JB, Roh JK, Kim KS, Choi JS, Cha SH, Kim H. Cetuximab in Combination with 5-Fluorouracil, Leucovorin and Irinotecan as a Neoadjuvant Chemotherapy in Patients with Initially Unresectable Colorectal Liver Metastases. Oncol Res Treat 2007;30:637-43. [DOI: 10.1159/000109957] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
163 Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Integrating Radioembolization (90Y Microspheres) Into Current Treatment Options for Liver Tumors: Introduction to the International Working Group Report. American Journal of Clinical Oncology 2012;35:81-90. [DOI: 10.1097/coc.0b013e3181ec60b8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
164 Jones RP, Hamann S, Malik HZ, Fenwick SW, Poston GJ, Folprecht G. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. European Journal of Cancer 2014;50:1590-601. [DOI: 10.1016/j.ejca.2014.02.024] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
165 Wang CC, Li J. An update on chemotherapy of colorectal liver metastases. World J Gastroenterol 2012; 18(1): 25-33 [PMID: 22228967 DOI: 10.3748/wjg.v18.i1.25] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
166 O’reilly DA, Poston GJ. Colorectal liver metastases: current and future perspectives. Future Oncology 2006;2:525-31. [DOI: 10.2217/14796694.2.4.525] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
167 Spaggiari M, Tulla KA, Aguiluz G, Di Cocco P, Castro Gil L, Benedetti E, Tzvetanov IG, Giulianotti PC. Robotic-assisted placement of hepatic artery infusion pump for the treatment of colorectal liver metastases: Role of indocyanine green (with video). Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00196-X. [PMID: 34674947 DOI: 10.1016/j.hbpd.2021.09.009] [Reference Citation Analysis]
168 Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, Petricoin E, Liotta L, Belluco C. Individualized therapy for metastatic colorectal cancer. J Intern Med 2013;274:1-24. [PMID: 23527888 DOI: 10.1111/joim.12070] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
169 Inoue Y, Miki C, Kusunoki M. Current directions in chemotherapy for colorectal cancer. J Gastroenterol 2006;41:821-31. [DOI: 10.1007/s00535-006-1873-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
170 Nordlinger B, Ducreux M, Wasan H, Pozzo C. The role of irinotecan in the treatment of colorectal cancer metastases: surgeons and oncologists in partnership. European Journal of Cancer Supplements 2004;2:27-33. [DOI: 10.1016/j.ejcsup.2004.04.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
171 Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670-1676. [PMID: 17470860 DOI: 10.1200/jco.2006.09.0928] [Cited by in Crossref: 767] [Cited by in F6Publishing: 296] [Article Influence: 51.1] [Reference Citation Analysis]
172 Adam R. Developing Strategies for Liver Metastases From Colorectal Cancer. Seminars in Oncology 2007;34:S7-S11. [DOI: 10.1053/j.seminoncol.2007.01.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
173 Power DG, Healey-bird BR, Kemeny NE. Regional Chemotherapy for Liver-Limited Metastatic Colorectal Cancer. Clinical Colorectal Cancer 2008;7:247-59. [DOI: 10.3816/ccc.2008.n.032] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
174 Downey RJ. Surgery for colorectal and sarcomatous pulmonary metastases: history, current management, and future directions. Thorac Surg Clin 2006;16:133-7, v-vi. [PMID: 16805202 DOI: 10.1016/j.thorsurg.2006.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
175 Gallagher DJ, Kemeny N. Improving Response and Outcomes for Patients With Liver-Limited Metastatic Colorectal Cancer. Clinical Colorectal Cancer 2010;9:S36-43. [DOI: 10.3816/ccc.2010.s.005] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
176 Davies JM, Goldberg RM. Optimum chemotherapy regimens for neoadjuvant therapy of hepatic colorectal metastases: Neoadjuvant Colorectal Liver Metastases. J Surg Oncol 2010;102:946-54. [DOI: 10.1002/jso.21653] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
177 Funaioli C, Pinto C, Di Fabio F, Santini D, Ceccarelli C, De Raffaele E, Fanti S, Castellucci P, Longobardi C, Buggi F, Martoni AA. 18FDG-PET Evaluation Correlates Better than CT with Pathological Response in a Metastatic Colon Cancer Patient Treated with Bevacizumab-Based Therapy. Tumori 2007;93:611-5. [DOI: 10.1177/030089160709300617] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
178 Champagne BJ, Delaney CP. Laparoscopy for metastatic colorectal cancer. Surg Oncol 2007;16:15-24. [PMID: 17548191 DOI: 10.1016/j.suronc.2007.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
179 Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev 2006;32:491-503. [PMID: 16959432 DOI: 10.1016/j.ctrv.2006.07.001] [Cited by in Crossref: 104] [Cited by in F6Publishing: 86] [Article Influence: 6.5] [Reference Citation Analysis]
180 Kobayashi A, Miyagawa S. Advances in therapeutics for liver metastasis from colorectal cancer. World J Gastrointest Oncol 2010; 2(10): 380-389 [PMID: 21160889 DOI: 10.4251/wjgo.v2.i10.380] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
181 Rusthoven CG, Schefter TE. Rationale for ablation of oligometastatic disease and the role of stereotactic body radiation therapy for hepatic metastases. Hepat Oncol 2014;1:81-94. [PMID: 30190943 DOI: 10.2217/hep.13.12] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
182 Alberts SR. Updated Options for Liver-Limited Metastatic Colorectal Cancer. Clinical Colorectal Cancer 2008;7:S58-62. [DOI: 10.3816/ccc.2008.s.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
183 Rougier P, Lepere C. Metastatic colorectal cancer: first- and second-line treatment in 2005. Semin Oncol. 2005;32:15-20. [PMID: 16360007 DOI: 10.1053/j.seminoncol.2005.07.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
184 D'Angelica MI, Correa-Gallego C, Paty PB, Cercek A, Gewirtz AN, Chou JF, Capanu M, Kingham TP, Fong Y, DeMatteo RP. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261:353-360. [PMID: 24646562 DOI: 10.1097/sla.0000000000000614] [Cited by in Crossref: 101] [Cited by in F6Publishing: 34] [Article Influence: 14.4] [Reference Citation Analysis]
185 Wicherts DA, Miller R, de Haas RJ, Bitsakou G, Vibert E, Veilhan LA, Azoulay D, Bismuth H, Castaing D, Adam R. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg. 2008;248:994-1005. [PMID: 19092344 DOI: 10.1097/sla.0b013e3181907fd9] [Cited by in Crossref: 248] [Cited by in F6Publishing: 79] [Article Influence: 19.1] [Reference Citation Analysis]
186 Goere D, Mariette C. [Key events from the 4th French-speaking congress on digestive and hepatobiliary surgery: synthesis of the oral communications and report of symposium. December 4-6 2008, Paris]. J Chir (Paris) 2009;146 Suppl 3:S117-30. [PMID: 19539809 DOI: 10.1016/S0021-7697(09)74041-4] [Reference Citation Analysis]
187 de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 Resection by Necessity for Colorectal Liver Metastases: Is It Still a Contraindication to Surgery? Annals of Surgery 2008;248:626-37. [DOI: 10.1097/sla.0b013e31818a07f1] [Cited by in Crossref: 79] [Cited by in F6Publishing: 112] [Article Influence: 5.6] [Reference Citation Analysis]
188 Duwe G, Knitter S, Pesthy S, Beierle AS, Bahra M, Schmelzle M, Schmuck RB, Lohneis P, Raschzok N, Öllinger R, Sinn M, Struecker B, Sauer IM, Pratschke J, Andreou A. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection. Eur J Surg Oncol 2017;43:1668-81. [PMID: 28599872 DOI: 10.1016/j.ejso.2017.05.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
189 Power DG, Kemeny NE. Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. Crit Rev Oncol Hematol. 2011;79:251-264. [PMID: 20970353 DOI: 10.1016/j.critrevonc.2010.08.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
190 Sugihara K, Uetake H. Therapeutic strategies for hepatic metastasis of colorectal cancer: overview. J Hepatobiliary Pancreat Sci. 2012;19:523-527. [PMID: 22706522 DOI: 10.1007/s00534-012-0524-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
191 Merkel S, Schellerer V, Weber K, Göhl J, Hohenberger W. Assessment of advances of outcome quality in colon carcinoma at a single center. Colorectal Cancer 2012;1:215-24. [DOI: 10.2217/crc.12.24] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
192 de Haas RJ, Wicherts DA, Andreani P, Pascal G, Saliba F, Ichai P, Adam R, Castaing D, Azoulay D. Impact of expanding criteria for resectability of colorectal metastases on short- and long-term outcomes after hepatic resection. Ann Surg. 2011;253:1069-1079. [PMID: 21451388 DOI: 10.1097/sla.0b013e318217e898] [Cited by in Crossref: 123] [Cited by in F6Publishing: 44] [Article Influence: 11.2] [Reference Citation Analysis]
193 Chan G, Hassanain M, Chaudhury P, Vrochides D, Neville A, Cesari M, Kavan P, Marcus V, Metrakos P. Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy. HPB (Oxford) 2010;12:277-84. [PMID: 20590898 DOI: 10.1111/j.1477-2574.2010.00170.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]